No Data
No Data
Venture Huikang (300451): Medical IT business grows steadily, new products and new businesses launch at an accelerated pace
Investment events: Recently, the company released its 2023 annual report and 2024 quarterly report: (1) 2023 revenue of 1,616 billion yuan, growth rate of 5.81%, net profit to mother of 37 million yuan, a year-on-year decrease of 13.93%
Venture Huikang (300451): Performance verification, recovery expectations, HI-HIS product release can be expected
Core view: 24Q1 results are in line with recovery expectations, and sales and management expenses are optimized. The company released its 2024 quarterly report. 24Q1 achieved revenue of 380 million yuan, an increase of 7.8% over the previous year; net profit to mother was 123
Chuangye Huikang (300451.SZ) announced first-quarter results, net profit of 12.3597 million yuan, an increase of 19.03% over the previous year
Chuangye Huikang (300451.SZ) released its report for the first quarter of 2024. The company achieved operating revenue during the period...
Venture Huikang (300451): Q1 performance gradually recovers, annual profit is expected to improve
First-quarter results began to recover. The company's annual profitability or inflection point released its 2024 quarterly report, achieving operating income of 375 million yuan, an increase of 7.76% over the previous year, and a net profit of 12.36 million yuan to mother, an increase of 19 million yuan over the previous year.
Chuangye Huikang (300451) 2023 Report Review: Steady Revenue Growth HI-HIS Towards a New Stage of Promotion
Matters: On April 13, 2024, the company released its 2023 annual report: achieved operating income of 1,616 billion yuan, up 5.81% year on year; net profit to mother was 37 million yuan, down 13.93% year on year;
Southwest Securities released a research report on April 21 stating that it maintains the Venture Huikang (300451.SZ) purchase rating, and the target price is 5.20 yuan. The main reasons for the rating include: 1) revenue growth has resumed, and profits a
Southwest Securities released a research report on April 21 stating that it maintains the Venture Huikang (300451.SZ) purchase rating, and the target price is 5.20 yuan. The main reasons for the rating include: 1) revenue growth has resumed, and profits are being pressured in the short term; 2) Hi-HiS is moving towards a new stage of nationwide promotion, which is expected to accelerate the release of performance; 3) further deepening collaboration with Philips to consolidate its leading edge in many ways. (Mainichi Keizai Shimbun)
No Data